Literature DB >> 15140940

Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

Jeannie Chin1, Jorge J Palop, Gui-Qiu Yu, Nobuhiko Kojima, Eliezer Masliah, Lennart Mucke.   

Abstract

Alzheimer's disease (AD), the most common neurodegenerative disorder, results in progressive degeneration of synapses and aberrant sprouting of axon terminals. The mechanisms underlying these seemingly opposing cellular phenomena are unclear. We hypothesized that Fyn kinase may play a role in one or both of these processes because it is increased in AD brains and because it is involved in synaptic plasticity and axonal outgrowth. We investigated the effects of Fyn on AD-related synaptotoxicity and aberrant axonal sprouting by ablating or overexpressing Fyn in human amyloid precursor protein (hAPP) transgenic mice. On the fyn+/+ background, hAPP/amyloid beta peptide (Abeta) decreased hippocampal levels of synaptophysin-immunoreactive presynaptic terminals (SIPTs), consistent with previous findings. On the fyn-/- background, hAPP/Abeta did not affect SIPTs. SIPT reductions correlated with hippocampal Abeta levels in hAPP/fyn+/+, but not hAPP/fyn-/-, mice suggesting that Fyn provides a critical link between hAPP/Abeta and SIPTs. Furthermore, overexpression of Fyn exacerbated SIPT reductions in hAPP mice. We also found that the susceptibility of mice to hAPP/Abeta-induced premature mortality was decreased by Fyn ablation and increased by Fyn overexpression. In contrast, axonal sprouting in the hippocampus of hAPP mice was unaffected. We conclude that Fyn-dependent pathways are critical in AD-related synaptotoxicity and that the pathogenesis of hAPP/Abeta-induced neuronal alterations may be mechanistically heterogenous.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140940      PMCID: PMC6729387          DOI: 10.1523/JNEUROSCI.0277-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  79 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Genetic deletion of Nogo/Rtn4 ameliorates behavioral and neuropathological outcomes in amyloid precursor protein transgenic mice.

Authors:  E Masliah; F Xie; S Dayan; E Rockenstein; M Mante; A Adame; C M Patrick; A F Chan; B Zheng
Journal:  Neuroscience       Date:  2010-04-28       Impact factor: 3.590

3.  Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Authors:  David A Gimbel; Haakon B Nygaard; Erin E Coffey; Erik C Gunther; Juha Laurén; Zachary A Gimbel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 4.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 5.  Beta-amyloid modulation of synaptic transmission and plasticity.

Authors:  Deepa V Venkitaramani; Jeannie Chin; William J Netzer; Gunnar K Gouras; Sylvain Lesne; Roberto Malinow; Paul J Lombroso
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

Review 6.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

7.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  EMBO J       Date:  2017-09-01       Impact factor: 11.598

Review 8.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

10.  Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein.

Authors:  Julie A Harris; Nino Devidze; Brian Halabisky; Iris Lo; Myo T Thwin; Gui-Qiu Yu; Dale E Bredesen; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.